A citation-based method for searching scientific literature

Massimiliano Ruscica, Lale Tokgözoğlu, Alberto Corsini, Cesare R Sirtori. Atherosclerosis 2019
Times Cited: 44







List of co-cited articles
438 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
43

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
31

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
27

PCSK9 induces a pro-inflammatory response in macrophages.
Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F G Cicero,[...]. Sci Rep 2018
98
27

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
20


New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
Zhi-Han Tang, Juan Peng, Zhong Ren, Jing Yang, Ting-Ting Li, Tao-Hua Li, Zuo Wang, Dang-Heng Wei, Lu-Shan Liu, Xi-Long Zheng,[...]. Atherosclerosis 2017
105
20

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto, Fernando Civeira, Marcus Flather, Robert J Glynn, Jean Gregoire, J Wouter Jukema,[...]. N Engl J Med 2017
374
18

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
18

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
237
18

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis,[...]. Lancet Diabetes Endocrinol 2017
288
15

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jennifer Robinson, Christie M Ballantyne, Ransi Somaratne, Jason Legg, Scott M Wasserman,[...]. N Engl J Med 2015
15

PCSK9 and inflammation: a review of experimental and clinical evidence.
Amir Abbas Momtazi-Borojeni, Sarvenaz Sabouri-Rad, Antonio M Gotto, Matteo Pirro, Maciej Banach, Zuhier Awan, George E Barreto, Amirhossein Sahebkar. Eur Heart J Cardiovasc Pharmacother 2019
47
15

A new dawn for managing dyslipidemias: The era of rna-based therapies.
C Macchi, C R Sirtori, A Corsini, R D Santos, G F Watts, M Ruscica. Pharmacol Res 2019
44
15

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
15

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
15

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
15

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Ahmed Zaid, Anna Roubtsova, Rachid Essalmani, Jadwiga Marcinkiewicz, Ann Chamberland, Josée Hamelin, Michel Tremblay, Hélène Jacques, Weijun Jin, Jean Davignon,[...]. Hepatology 2008
277
13

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.
Jonathan Cohen, Alexander Pertsemlidis, Ingrid K Kotowski, Randall Graham, Christine Kim Garcia, Helen H Hobbs. Nat Genet 2005
899
13

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
13

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
13

PCSK9 as a Positive Modulator of Platelet Activation.
Marina Camera, Laura Rossetti, Silvia S Barbieri, Ilaria Zanotti, Barbara Canciani, Daniela Trabattoni, Massimiliano Ruscica, Elena Tremoli, Nicola Ferri. J Am Coll Cardiol 2018
34
17

Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Tsuyoshi Nozue. J Atheroscler Thromb 2017
52
13

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Keith R Walley, Katherine R Thain, James A Russell, Muredach P Reilly, Nuala J Meyer, Jane F Ferguson, Jason D Christie, Taka-aki Nakada, Chris D Fjell, Simone A Thair,[...]. Sci Transl Med 2014
211
13

PCSK9: From Basic Science Discoveries to Clinical Trials.
Michael D Shapiro, Hagai Tavori, Sergio Fazio. Circ Res 2018
98
13

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Nabil G Seidah, Suzanne Benjannet, Louise Wickham, Jadwiga Marcinkiewicz, Stephanie Belanger Jasmin, Stefano Stifani, Ajoy Basak, Annik Prat, Michel Chretien. Proc Natl Acad Sci U S A 2003
805
11

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Stephen J Nicholls, Rishi Puri, Todd Anderson, Christie M Ballantyne, Leslie Cho, John J P Kastelein, Wolfgang Koenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang,[...]. JAMA 2016
515
11

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Steven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, Robert S Rosenson, Sam J Lehman, Naveed Sattar, David Preiss, Eric Bruckert, Richard Ceška, Norman Lepor,[...]. JAMA 2016
288
11

Genetic and metabolic determinants of plasma PCSK9 levels.
Susan G Lakoski, Thomas A Lagace, Jonathan C Cohen, Jay D Horton, Helen H Hobbs. J Clin Endocrinol Metab 2009
349
11

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Anne C Goldberg, Lawrence A Leiter, Erik S G Stroes, Seth J Baum, Jeffrey C Hanselman, LeAnne T Bloedon, Narendra D Lalwani, Pragna M Patel, Xin Zhao, P Barton Duell. JAMA 2019
141
11

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Chiara Macchi, Nicola Ferri, Chiara Favero, Laura Cantone, Luisella Vigna, Angela C Pesatori, Maria G Lupo, Cesare R Sirtori, Alberto Corsini, Valentina Bollati,[...]. Eur J Prev Cardiol 2019
27
18

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.
Susan Kühnast, José W A van der Hoorn, Elsbet J Pieterman, Anita M van den Hoek, William J Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J Wouter Jukema,[...]. J Lipid Res 2014
126
11

Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.
Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Changqing Sun, Yannian Wang, Jawahar L Mehta. Antioxid Redox Signal 2015
101
11

Cross-talk between LOX-1 and PCSK9 in vascular tissues.
Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Jiwani Shahanawaz, Robert J Shmookler Reis, Kattayi I Varughese, Tatsuya Sawamura, Jawahar L Mehta. Cardiovasc Res 2015
128
11

Local effects of human PCSK9 on the atherosclerotic lesion.
Ilaria Giunzioni, Hagai Tavori, Roman Covarrubias, Amy S Major, Lei Ding, Youmin Zhang, Rachel M DeVay, Liang Hong, Daping Fan, Irene M Predazzi,[...]. J Pathol 2016
100
11

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
Jin M Cheng, Rohit M Oemrawsingh, Hector M Garcia-Garcia, Eric Boersma, Robert-Jan van Geuns, Patrick W Serruys, Isabella Kardys, K Martijn Akkerhuis. Atherosclerosis 2016
92
11

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Nicola Ferri, Gianpaolo Tibolla, Angela Pirillo, Francesco Cipollone, Andrea Mezzetti, Stefano Pacia, Alberto Corsini, Alberico Luigi Catapano. Atherosclerosis 2012
160
11

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
158
11

Clinical approach to the inflammatory etiology of cardiovascular diseases.
Massimiliano Ruscica, Alberto Corsini, Nicola Ferri, Maciej Banach, Cesare R Sirtori. Pharmacol Res 2020
30
16

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Christine Landlinger, Marianne G Pouwer, Claudia Juno, José W A van der Hoorn, Elsbet J Pieterman, J Wouter Jukema, Guenther Staffler, Hans M G Princen, Gergana Galabova. Eur Heart J 2017
120
11

Inflammation stimulates the expression of PCSK9.
Kenneth R Feingold, Arthur H Moser, Judy K Shigenaga, Sophie M Patzek, Carl Grunfeld. Biochem Biophys Res Commun 2008
152
11


Cognitive Function in a Randomized Trial of Evolocumab.
Robert P Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R Pedersen,[...]. N Engl J Med 2017
246
9

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Robert Dufour, Mahir Karakas, Tim Hall, Roland P T Troquay, Traci Turner, Frank L J Visseren,[...]. N Engl J Med 2017
431
9

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Shirya Rashid, David E Curtis, Rita Garuti, Norma N Anderson, Yuriy Bashmakov, Y K Ho, Robert E Hammer, Young-Ah Moon, Jay D Horton. Proc Natl Acad Sci U S A 2005
517
9

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.
Chiara Caselli, Serena Del Turco, Rosetta Ragusa, Valentina Lorenzoni, Michiel De Graaf, Giuseppina Basta, Arthur Scholte, Raffaele De Caterina, Danilo Neglia. Cardiovasc Diabetol 2019
22
18

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
Stephen L Pinkosky, Roger S Newton, Emily A Day, Rebecca J Ford, Sarka Lhotak, Richard C Austin, Carolyn M Birch, Brennan K Smith, Sergey Filippov, Pieter H E Groot,[...]. Nat Commun 2016
153
9

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
Nicola Ferri, Alberto Corsini, Chiara Macchi, Paolo Magni, Massimiliano Ruscica. Transl Res 2016
39
10

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Ulrich Laufs, Maciej Banach, G B John Mancini, Daniel Gaudet, LeAnne T Bloedon, Lulu Ren Sterling, Stephanie Kelly, Erik S G Stroes. J Am Heart Assoc 2019
134
9

Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Maria J Gutierrez, Noah L Rosenberg, Diane E Macdougall, Jeffrey C Hanselman, Janice R Margulies, Poul Strange, Mark A Milad, Scott J McBride, Roger S Newton. Arterioscler Thromb Vasc Biol 2014
99
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.